Lapatinib is classified as a signal transduction inhibitor - tyrosine kinase inhibitor, inhibitor of EGFR and HER2. Lapatinib is marketed as Tykerb and is used in the treatment of metastatic breast cancer that is HER-2 positive. The drug may also be used in combination with other chemotherapy drugs or for the treatment of other cancers.
Submit only sites about the drug, Lapatinib, also known as Tykerb.